Want to see BNR full AI Analyst Report?
BNR Stock Chart & Stats
$10.44
$0.45(5.03%)
At close: 4:00 PM EDT
$10.44
$0.45(5.03%)
Day’s Range― - ―
52-Week Range$6.79 - $41.72
Previous Close$9.27
Volume457.00
Average Volume (3M)47.59K
Market Cap
$129.27M
Enterprise Value$35.78M
Total Cash (Recent Filing)$419.26M
Total Debt (Recent Filing)$45.13M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-64.30
Shares Outstanding8,813,858
10 Day Avg. Volume24,412
30 Day Avg. Volume47,586
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.28
Price to Sales (P/S)0.28
P/FCF Ratio-4.51
Enterprise Value/Market Cap0.28
Enterprise Value/Revenue0.07
Enterprise Value/Gross Profit0.10
Enterprise Value/Ebitda-0.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsSustained gross margins in the mid-70% range indicate attractive underlying economics for BNR’s NGS testing and services. This provides a foundation for operating leverage if revenue stabilizes and allows more of each incremental dollar of sales to support research, commercialization, and eventual profitability.
Low Financial LeverageVery low leverage limits mandatory financing costs and reduces solvency risk while the company works toward profitability. A relatively unlevered balance sheet also preserves flexibility to fund product development, regulatory efforts, and commercial expansion without excessive dependence on debt.
Regulatory Product PipelineProgress through China’s CMDE priority and special review pathways could expand BNR’s approved product portfolio and strengthen its clinical testing position. Additional registered kits may support broader adoption, improve commercial reach, and create a more durable base for future oncology testing revenue.
Bears Say
Persistent Cash BurnContinued negative operating and free cash flow means BNR is not yet funding its operations internally. The deterioration in TTM 2026 free cash flow increases reliance on external funding and may constrain investment capacity until the business achieves sustainable cash profitability.
Inconsistent Revenue And MixUneven revenue performance across clinical and pharma-related activities reduces earnings visibility and makes growth less predictable. Declines in central lab activity and volatility in pharma R&D may offset improvements elsewhere, limiting the consistency needed to absorb fixed costs and reach profitability.
Unprofitable And Negative ReturnsBNR continues to generate losses and negative returns on shareholder capital despite strong gross margins. Persistent unprofitability can erode equity over time, restrict internally funded growth, and indicate that operating expenses and commercialization investments have not yet been covered by gross profit.
Burning Rock Biotech News
BNR FAQ
What was Burning Rock Biotech Ltd.’s price range in the past 12 months?
Burning Rock Biotech Ltd. lowest stock price was $6.79 and its highest was $41.72 in the past 12 months.
What is Burning Rock Biotech Ltd.’s market cap?
Burning Rock Biotech Ltd.’s market cap is $129.27M.
When is Burning Rock Biotech Ltd.’s upcoming earnings report date?
Burning Rock Biotech Ltd.’s upcoming earnings report date is Nov 17, 2026 which is in 27 days.
How were Burning Rock Biotech Ltd.’s earnings last quarter?
Burning Rock Biotech Ltd. released its earnings results on Sep 02, 2026. The company reported -$0.249 earnings per share for the quarter.
Is Burning Rock Biotech Ltd. overvalued?
According to Wall Street analysts Burning Rock Biotech Ltd.’s price is currently Overvalued.
Does Burning Rock Biotech Ltd. pay dividends?
Burning Rock Biotech Ltd. does not currently pay dividends.
What is Burning Rock Biotech Ltd.’s EPS estimate?
Burning Rock Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Burning Rock Biotech Ltd. have?
Burning Rock Biotech Ltd. has 8,813,858 shares outstanding.
What happened to Burning Rock Biotech Ltd.’s price movement after its last earnings report?
Burning Rock Biotech Ltd. reported an EPS of -$0.249 in its last earnings report. Following the earnings report the stock price went down -0.759%.
Which hedge fund is a major shareholder of Burning Rock Biotech Ltd.?
Currently, no hedge funds are holding shares in BNR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Burning Rock Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
52.86%
12-Months-Change
Fundamentals
Return on Equity
-12.97%
Trailing 12-Months
Asset Growth
-3.91%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Burning Rock Biotech Ltd.
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.